Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study

Journal of the American Academy of Dermatology

Volumn 79, Issue 6, 2018, Pages 1047-1052

  Min Lee, Charles Kyung ^a   Li, Shufeng ^a   Tran, Duy Cong ^a   Zhu, Gefei Alex ^a   Kim, Jinah ^a   Kwong, Bernice Y ^a   Chang, Anne Lynn S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

checkpoint inhibitor; dermatitis; immunotherapy; inhibitor; lichenoid; nonmelanoma skin cancer; PD 1; PD L1; programmed death 1; programmed death ligand 1; reaction pattern; spongiotic

Indexed keywords

ATEZOLIZUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; STEROID; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR PROTEIN;

AGED; ARTICLE; BASAL CELL CARCINOMA; BILE DUCT CANCER; BLADDER CANCER; BREAST CANCER; BULLOUS DERMATITIS; CANCER PROGNOSIS; CANCER SURVIVAL; CASE CONTROL STUDY; CD8+ T LYMPHOCYTE; CLINICAL OUTCOME; COLORECTAL CANCER; CUTANEOUS MELANOMA; DERMATITIS; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC MALIGNANCY; HISTOLOGY; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LARYNX CANCER; LICHENOID ERUPTION; LIVER CANCER; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MAXILLA CANCER; MEDICAL RECORD REVIEW; MOUTH CANCER; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; NON SMALL CELL LUNG CANCER; OROPHARYNX CANCER; OVERALL SURVIVAL; PLEURA CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SALIVARY GLAND CANCER; SEZARY SYNDROME; SKIN BIOPSY; SKIN CARCINOMA; SMALL CELL LUNG CANCER; SMALL INTESTINE CANCER; STEROID THERAPY; SYSTEMIC THERAPY; THYROID CANCER; TOPICAL TREATMENT; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; ADULT; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; DRUG ERUPTION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEOPLASM; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; DRUG ERUPTIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LICHENOID ERUPTIONS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS; NIVOLUMAB; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85050862025     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2018.05.035     Document Type: Article

References (19)

1. Hamid, O., Robert, C., Daud, A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:2 (2013), 134–144.
2. Ilie, M., Hofman, P., Atezolizumab in advanced non-small lung cancer. J Thorac Dis 9:10 (2017), 3603–3606.
3. Ghebeh, H., Mohammed, S., Al-Omair, A., et al. The B7-H1 (PD-L1) T lymphocyte inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8 (2006), 190–198.
4. Hamanishi, J., Mandai, M., Iwasaki, M., et al. Programmed cell death1ligand1and tumor infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 104 (2007), 3360–3365.
5. Wu, C., Zhu, Y., Jiang, J., Zhao, J., Zhang, X.G., Xu, N., Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108 (2006), 19–24.
6. Inman, B.A., Sebo, T.J., Frigola, X., et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109 (2007), 1499–1505.
7. Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., Ueda, S., Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56 (2007), 1173–1182.
8. Sanlorenzo, M.I., Daud, A., Algazi, A., et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151:11 (2015), 1206–1212.
9. Hua, C., Boussemart, L., Mateus, C., et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152:1 (2016), 45–51.
10. Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:26 (2012), 2443–2454.
11. Reck, M., Delvys, R.A., Robinson, A., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375 (2016), 1823–1833.
12. Keytruda (pembrolizumab) [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2014.
13. Opdivo (nivolumab) [package insert]. Lawrenceville, NJ: Bristol-Myers Squibb Company; 2014.
14. Tecentriq (atezolizumab) [package insert]. South San Francisco, CA: Genetech, Inc; 2016.
15. Schaberg, K.B., Novoa, R., Wakelee, H.A., et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol 43 (2016), 339–346.
16. Freites-Martinez, A., Kwong, B.Y., Rieger, K.E., et al. Eruptive keratoacanthomas associated with pembrolizumab therapy. JAMA Dermatol 153:7 (2017), 694–697.
17. Quaglino, P., Marenco, F., Osella-Abate, S., et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol 21:2 (2010), 409–414.
18. Perret, R.E., Josselin, N., Knol, A.C., et al. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma. Int J Dermatol 56 (2017), 527–533.
19. Kaunitz, G., Loss, M., Rizvi, H., et al. Cutaneous eruptions in patients receiving immune checkpoint blockade: clinicopathologic analysis of the nonlichenoid histologic pattern. Am J Surg Pathol 41:10 (2017), 1381–1389.